Zura Bio
Clinical trials sponsored by Zura Bio, explained in plain language.
Clinical-stage biotech developing immunology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody drug aims to calm painful skin condition Results expected Nov 2026 (estimated)
- New antibody drug aims to halt Scleroderma's damage Results expected May 2027 (estimated) May already have reported ↗
-
New antibody drug aims to halt Scleroderma's damage
Disease control OngoingThis Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC